Among the affected medicines was cycloserine, used as a second-line treatment for multidrugresistant (MDR) and extensively-drug-resistant (XDR) tuberculosis, rights to which were acquired in August, 2015, by Rodelis Therapeutics. Rodelis raised the price for 30-tablet blister packs of cycloserine from US$500 to nearly $11 000, but in the face of nationwide outcry over the move, returned rights ...